The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry.
Rungroj KrittayaphongArjbordin WinijkulKomsing MethavigulPoom SairatC O O L-A F InvestigatorsPublished in: Cardiovascular therapeutics (2022)
Antiplatelet was used in 890 (28.3%) AF, of whom 582 (18.5%) received antiplatelet alone, and 308 (9.8%) received antiplatelet and OAC. OAC plus antiplatelet significantly increased the risk of death without additional stroke prevention benefit. Antiplatelet alone should not be used in patients with AF.